Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 8/20 | 0.56 |
| ▸ | CASP1 | P29466 | 9/20 | 0.52 |
| ▸ | CASP7 | P55210 | 5/20 | 0.52 |
| ▸ | CASP9 | P55211 | 2/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | CASP4 | P49662 | 2/20 | 0.51 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472606 | 0.91 | CASP3 (0.56) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL17494194 | 0.91 | CASP3 (0.56) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL24213871 | 0.91 | CASP3 (0.56) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL14646635 | 0.91 | CASP3 (0.56) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL3140616 | 0.90 | CASP3 (0.62) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL614741 | 0.90 | CASP3 (0.62) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL18740358 | 0.89 | CASP3 (0.58) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL3692638 | 0.87 | CASP3 (0.58) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL7112627 | 0.87 | CASP3 (0.58) | CASP3CASP1CASP7CASP9CASP8 | |
| SCHEMBL7423249 | 0.86 | CASP1 (0.54) | CASP3CASP1CASP7REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227976-A1 | PROCESS FOR SYNTHESIZING ASPARTIC AND GLUTAMIC ACID DERIVATIVES ESPECIALLY USEFUL AS INTERMEDIATES IN THE MANUFACTURE OF A CASPASE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATEAD (US) | 2008-09-18 | — | — | US | disclosed |
| US-7335792-B2 | Process for synthesizing aspartic and glutamic acid derivatives especially useful as intermediates in the manufacture of a caspase inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227976-A1 | PROCESS FOR SYNTHESIZING ASPARTIC AND GLUTAMIC ACID DERIVATIVES ESPECIALLY USEFUL AS INTERMEDIATES IN THE MANUFACTURE OF A CASPASE INHIBITOR | CASP1, CASP5, CASP2 | CASP3 9/4885CASP1 1/4885CASP7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.